Литература

1. Владимирская Е.Б., Масчан А.А., Румянцев А.Г. Апоптоз и его роль в развитии опухолевого роста. Гематол трансфузиол 1997; 5: 4-9.

2. Лушников Е.Ф., Абросимов А.Ю. Сравнительная морфология апоптоза и некроза клеток опухолей. Тезисы 1 Белорусского съезда патологоанатомов и судебных медиков. Минск 1990-1991; 2: 299-300.

3. Маянский А.Н., Маянский Н.А., Абаджиди М.А., Заславская М.И. Апоптоз: начало будущего. Ж микробиол 1997; 2: 88-94.

4. Метелица И.С. Иммунологический фенотип лимфоцитов периферической крови при патологии женской репродуктивной системы. Дис. ... канд. мед. наук. М 1996; 95.

5. Новожилова А.П., Плужников Н.Н., Новиков В.С. и др. Программированная клеточная гибель. СПб: Наука 1996; 276.

6. Райхлин Н.Т., Смирнова Е.А., Перевощиков А.Г. Апоптоз и его роль в механизмах регуляции роста опухолевых клеток с множественной лекарственной устойчивостью. Арх патол 1996; 2: 3-8.

7. Робинсон М.В., Труфакин В.А. Апоптоз клеток иммунной системы. Успехи соврем биол 1991; 111: 2: 246-259.

8. Романенко А.М. Апоптоз и рак. Арх патол 1996; 3: 18-22.

9. Селицкая Р.П., Богодельникова И.В., Конова И.А. и др. Оценка экспрессии активационных маркеров на клеточных элементах очага туберкулезного воспаления в легком. Туберкулез и экология 1996; 2: 37-39.

10. Сыркин А.Б., Герасимова Г. К., Барышников Ю. А. и соавт. Экспериментальная химиотерапия злокачественных опухолей на современном этапе. Вопр онкол 1995; 2: 41-45.

11. Умнова Н.В., Москалева Е.Ю., Порошенко Г.Г. Репарация ДНК у больных хроническими неспецифическими воспалительными заболеваниями легких. Бюлл экспер биол и мед 1986; 107: 12: 743-745.

12. Хоменко А.Г., Ковальчук Л.В., Мишин В.Ю. и др. Повышенный апоптоз иммунокомпетентных клеток как один из возможных механизмов в развитии иммунодефицита у больных остропрогрессирующим туберкулезом. Пробл туб 1996; 6: 6-10.

13. Чередеев А.Н., Ковальчук Л.В. Патогенетический принцип оценки иммунной системы человека: современные проблемы. Сб. трудов "Современные проблемы аллергологии, клинической иммунологии и иммунофармакологии", 1-я нац. конф. Росс. ассоц. аллергологов и клинических иммунологов. М 1997; 74-80.

14. Ярыгин Н.Е., Кораблев А.В. Значение программированной гибели эндотелия в построении внутриорганного кровеносного русла в эмбриогенезе человека. Арх патол 1995; 6: 39-44.

15. Ackerman R.C., Johnson G.A., Van-Kirk E.A. et al. Induction of apoptotic or lytic death in an ovarian adenocarcinoma cell line by antibodies generated against a synthetic N-terminal extracellular domain gonadotropin-releasing hormone receptor peptide. Cancer Lett 1994; 81: 2: 177-184.

16. Bamberger A.M., Schulte H.M., Thuneke I. et al. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 1997; 82: 9: 3173-3175.

17. Bell C.G.H. Apoptosis in T and B lymphocytes life cycles. Biochim Soc Trans 1995; 23: 2: 214.

18. Bu S.Z., Yin D.L., Ren X.H. et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997; 79: 10: 1944-1950.

19. Burke F., East N., Upton C. et al. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer 1997; 33: 7: 1114-1121.

20. Butz K., Geisen C., Ullmann A. et al. Cellular responses of HPV-positive cancer cells to genotoxic anticancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 1996; 68: 4: 506-513.

21. Chen Z., Naito M., Mashima T., Tsuruo T. Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Cancer Res 1996; 56: 22: 5224-5229.

22. Debernardis D., Sire E.G., De-Feudis P. et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57: 5: 870-874.

23. Deshane J., Grim J., Loechel S. et al. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gen Ther 1996; 3: 2: 89-98.

24. Diebold J., Baretton G., Felchner M. et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996; 105: 3: 341-349.

25. Eliopoulos A.G., Kerr D.J., Herod J. et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995; 11: 7: 1217-1228.

26. Fajac A., Da-Silva J., Ahomadegbe J.C. et al. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 1996; 68: 1: 67-74.

27. Ferrandina G., Melichar B., Loercher A. et al. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 1997; 57: 19: 4309-4315.

28. Filippovich I.V., Sorokina N.I., Robillard N., Chatal J.F. Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids. Int J Cancer 1997; 72: 5: 851-859.

29. Frankel A., Buckman R., Kerbel R.S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997; 57: 12: 2388-2393.

30. Furuya H., Yabushita H., Noguchi M., Nakanishi M. Apoptosis and cell growth fraction in normal, dysplastic and neoplastic squamous epithelium of uterine cervix. Nippon Sanka Fujinka Gakkai Zasshi 1995; 47: 2: 141-148.

31. Garzetti G.G., Ciavattini A., Provinciali M. et al. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Anticancer Res 1996; 16: 5B: 3229-3234.

32. Gibb R.K., Taylor D.D., Wan T. et al. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 1997; 65: 1: 13-22.

33. Gotlieb W.H., Watson J.M., Rezai A. et al. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol 1994; 170: 4: 1121-1128. (discussion 1128-1130).

34. Havrilesky L.J., Elbendary A., Hurteau J.A. et al. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 1995; 85: 6: 1007-1010.

35. Havrilesky L.J., Hurteau J.A., Whitaker R.S. et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res 1995; 55: 4: 944- 948.

36. Heatley M.K. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology 1995; 27: 5: 469-472.

37. Heatley M.K. A high apoptotic index occurs in subtypes of endometrial adenocarcinoma associated with a poor prognosis. Pathology 1997; 29: 3: 272-275.

38. Higashijima T., Kataoka A., Nishida T., Yakushiji M. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 1996; 68: 1-2: 169-173.

39. Huang S.C., Chou C.Y., Lin Y.S. et al. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1997; 177: 2: 417-424.

40. Hunt K.K., Deng J., Liu T.J. et al. Adenovirus-mediated overex-pression of the transcription factor E₂F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997; 57: 21: 4722-4726.

41. Isacson C., Kessis T.D., Hedrick L., Cho K.R. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996; 56: 4: 669-674.

42. Karlsson L., Leser G., Ryd W., Horvath G. Estradiol induces DNA fragmentation in a human endometrial adenocarcinoma with estradiol-inhibited growth phenotype. Anticancer Res 1997; 17: 5A: 3259-3263.

43. Kerr Y.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 2: 239-257.

44. Kim C.Y., Tsai M.H., Osmanian C. et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997; 57: 19: 4200- 4204.

45. Kleinman D., Douvdevani A., Schally A.V. et al. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. Am J Obstet Gynecol 1994; 170: 1: Pt 1: 96-102.

46. Kuwano K., Kunitake R., Kawasaki M. et al. P21/Cip/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulnonary fibrosis. Am J Responce Crit Care Med 1996; 154: 477-483.

47. Kuwashima Y., Kobayashi Y., Kawarai A. et al. Expression of bcl-2 and apoptotic DNA fragmentation in human endometrial adenocarcinoma cells. Anticancer Res 1996; 16: 5B: 3221- 3224.

48. Kuwashima Y., Kobayashi Y., Kawarai A. et al. Apoptosis in human endometrial adenocarcinoma: comparison of nick end labeling and Le(y) antigen immunostaining method. Anticancer Res 1996; 16: 5B: 3225-3228.

49. Kuwashima Y., Kobayashi Y., Kawarai A. et al. Occurrence of apoptotic DNA fragmentation in quiescent and proliferating cells in human endometrial adenocarcinoma tissues and the influence of apoptosis-suppressing effects of bcl-2 products. Anticancer Res 1997; 17: 5B: 3737-3741.

50. Lafon C., Mathieu C., Guerrin M. et al. Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ 1996; 7: 8: 1095-1104.

51. Levine E.L., Renehan A., Gossiel R. et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995; 37: 1: 1-9.

52. Mathieu C., Jozan S., Mazars P. et al. Density-dependent induction of apoptosis by transforming growth factor-beta 1 in a human ovarian carcinoma cell line. Exp Cell Res 1995; 216: 1: 13-20.

53. Miyawaki T., Uehara T., Nibu R. et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149: 3753-3758.

54. Oridate N., Lotan D., Mitchell M.F. et al. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. J Cell Biochem Suppl 1995; 23: 80-86.

55. Ormerod M.G., O'Neill C., Robertson D. et al. cis-Diammin-edichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1996; 37: 5: 463-471.

56. Owen-Schaub L.B. Fas/APO-1: A cell surface protein mediating apoptosis. Cancer Bull 1994; 46: 2: 141-145.

57. Saegusa M., Kamata Y., Isono M., Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 1996; 180: 3: 275-282.

58. Sanchez-Perez A.M., Soriano S., Clarke A.R., Gaston K. Disruption of the human papillomavirus type 16 E₂ gene protects cervical carcinoma cells from E₂F-induced apoptosis. J Gen Virol 1997; 78 (Pt 11): 3009-3018.

59. Sarraf С.E., Bowen I.D. Kinetic studies on a murine sarcoma and an analysis of apoptosis. Br J Cancer 1986; 54: 989-998.

60. Sheets E.E., Crum C.P., Yeh J. Association between cervical neoplasia and apoptosis as detected by in situ nuclear labeling. Gynecol Oncol 1996; 63: 1: 94-100.

61. Sheets E.E., Yeh J. The role of apoptosis in gynaecological malignancies. Ann Med 1997; 29: 2: 121-126.

62. Shoji Y., Saegusa M., TakanoY. et al. Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. J Clin Pathol 1996; 49: 2: 134-138.

63. Soini Y., Paakko P. Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Human Pathol 1996; 27: 11: 1221-1226.

64. Spinozzi F., Forenza N., Agen E. et al. CD30 Th2 allergen-specific Y T lymphocytes are increased in bronchoalveolar lavage (BAL) fluid of allergic asthma patients and sensitive to steroid-induced apoptosis. Eur Resp J 1995; 8: Suppl 19: 1874.

65. Trauth B.C., Klas C., Peters A.M.J. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 2: 301.

66. Ueda M., Kumagai K., Ueki K. et al. Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. Int J Cancer 1997; 71: 4: 668-674.

67. Uslu R., Jewett A., Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to antifas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 1996; 62: 2: 282-291.

68. Wheeler J.A., Stephens L.C., Tornos C. et al. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1995; 32: 5: 1487-1493.

69. Yamasaki F., Tokunaga O., Sugimori H. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 1997; 66: 3: 439-448.

70. Yunehara S., Nishimura Y., Kishi S., Ishii A. Expression and function of apoptosis antigen Fas on T cells in thymus and peryphery. Tiss antigens 1993; 42: 4: 253.